PART I Our Business We are a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases, driven by our deep commitment to improving the lives of people living with these conditions. We have built a robust commercial infrastructure to support the successful commercialization of ORLADEYO, an oral, once-daily therapy discovered and developed internally for the prevention of HAE attacks. Our business strategy includes leve...
Q2 FY2026 — expected 2026-09-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001628280-26-012240 | EDGAR | 87K words |
| 2025-02-25 | 2024-12-31 | 0001628280-25-007715 | EDGAR | — |
| 2024-02-27 | 2023-12-31 | 0001628280-24-007205 | EDGAR | — |
| 2023-02-27 | 2022-12-31 | 0001628280-23-005259 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0001171843-22-001460 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001171843-21-001411 | EDGAR | — |
| 2020-03-13 | 2019-12-31 | 0001171843-20-001710 | EDGAR | — |
| 2019-03-14 | 2018-12-31 | 0001171843-19-001727 | EDGAR | — |
| 2018-03-12 | 2017-12-31 | 0001171843-18-001855 | EDGAR | — |
| 2017-02-27 | 2016-12-31 | 0001171843-17-001159 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-05 | 2026-06-30 | 0001628280-26-053300 | EDGAR | — |
| 2025-11-04 | 2025-09-30 | 0001628280-25-048785 | EDGAR | 61K words |
| 2025-08-05 | 2025-06-30 | 0001628280-25-037795 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0001628280-25-022658 | EDGAR | — |
| 2024-11-05 | 2024-09-30 | 0001628280-24-045364 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0001628280-24-035170 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0001628280-24-021069 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0001628280-23-037847 | EDGAR | — |
| 2023-08-07 | 2023-06-30 | 0001628280-23-027820 | EDGAR | — |
| 2023-05-08 | 2023-03-31 | 0001628280-23-016458 | EDGAR | — |
| 2022-11-04 | 2022-09-30 | 0001628280-22-028463 | EDGAR | — |
| 2022-08-05 | 2022-06-30 | 0001628280-22-021373 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-05 | 0001171843-26-005223 | EDGAR | — |
| 2026-02-26 | 0001171843-26-001119 | EDGAR | 5K words |
| 2026-01-23 | 0001140361-26-002200 | EDGAR | — |
| 2026-01-12 | 0001171843-26-000213 | EDGAR | — |
| 2026-01-09 | 0001171843-26-000154 | EDGAR | — |
| 2025-12-12 | 0001171843-25-007909 | EDGAR | — |
| 2025-12-11 | 0001171843-25-007878 | EDGAR | — |
| 2025-12-03 | 0001140361-25-044110 | EDGAR | — |
| 2025-11-03 | 0001171843-25-006881 | EDGAR | — |
| 2025-10-14 | 0001140361-25-038031 | EDGAR | — |
262 total filings indexed. 230 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000882796 |
| Ticker | BCRX |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.biocryst.com |
| Listed | 1994-03-03 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/BCRX (~200 tokens, structured JSON with cryptographic provenance)